Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Toronto Stock Exchange  >  Cardiome Pharma Corp    COM   CA14159U3010

CARDIOME PHARMA CORP (COM)
Mes dernières consult.
Most popular
  Report  
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Toronto Stock Exchange
04/16/2018 04/17/2018 04/18/2018 04/19/2018 04/20/2018 Date
2.95(c) 3(c) 3.02(c) 2.96(c) 2.92(c) Last
4 260 4 100 28 561 12 600 12 100 Volume
-1.01% +1.69% +0.67% -1.99% -1.35% Change
More quotes
Financials (CAD)
Sales 2018 40,3 M
EBIT 2018 -26,9 M
Net income 2018 -27,4 M
Debt 2018 -
Yield 2018 -
Sales 2019 59,9 M
EBIT 2019 -15,8 M
Net income 2019 -13,1 M
Debt 2019 -
Yield 2019 -
P/E ratio 2018 -
P/E ratio 2019
Capi. / Sales2018 2,53x
Capi. / Sales2019 1,70x
Capitalization 102 M
More Financials
Company
Cardiome Pharma Corp. is a pharmaceutical company, which engages in the provision of development and commercialization of medical products.It focuses on cardiovascular therapies that will improve the quality of life and health of patients suffering from heart disease.It offers the Brinavess and... 
Sector
Pharmaceuticals
Calendar
05/09 | 06:30pmShareholder meeting
More about the company
Surperformance© ratings of Cardiome Pharma Corp
Trading Rating : Investor Rating :
More Ratings
Latest news on CARDIOME PHARMA CORP
04/12CARDIOME PHARMA : Announces Fifteen Xydalba™ and Zevtera® Abstracts at ECC..
PR
04/07CARDIOME PHARMA : Announces Amendment to Term Loan Agreement with CRG-Managed Fu..
PR
04/02CARDIOME PHARMA : Highlights Partner SteadyMed's Progress Towards Trevyent NDA R..
PR
03/28CARDIOME PHARMA : Announces Recent Insider Purchases
PR
03/22CARDIOME PHARMA CORP : Cardiome Pharma Agrees to Sell Drug Portfolio, Analysts T..
AC
03/22CARDIOME PHARMA : Health Canada Accepts Cardiome's Xydalba New Drug Submission a..
PR
03/22CARDIOME PHARMA CORP : Blog Exposure - Cipher to Acquire Cardiome’s Canadian Bus..
AC
03/13CARDIOME PHARMA : Reports Fourth Quarter and Full Year 2017 Financial Results
PR
03/13CARDIOME PHARMA CORP : Cardiome Pharma Corp. to Host Earnings Call
AC
03/06CARDIOME PHARMA : to Hold Fourth Quarter and Full Year 2017 Financial Results Co..
PR
More news
Sector news : Biopharmaceuticals
04/20GRAIN HIGHLIGHTS : Top Stories of the Day
DJ
04/20Japan's Takeda sweetens $62 billion Shire offer
RE
04/20SHIRE PLC SHIRE PLC : Statement Re Proposal From -2-
DJ
04/20SHIRE PLC SHIRE PLC : Statement Re Proposal From Takeda Pharmaceutical Company L..
DJ
04/20Generics group Alvogen puts Eastern European operations up for sale - sources
RE
More sector news : Biopharmaceuticals
Latest Tweets
04/13$CRME - Analysts Expect Cardiome Pharma Co. #CRME to Announce -$0.22 Earnings.. 
04/13Analysts Expect Cardiome Pharma Co. $CRME to Announce -$0.22 Earnings Per Sha.. 
04/09Cardiome Pharma $CRME Receives Media Sentiment Rating of 0.21  
04/08HC Wainwright Analysts Give Cardiome Pharma $CRME a $10.00 Price Target  
04/07Cardiome Pharma : Announces Amendment to Term Loan Agreement with CRG-Managed.. 
More tweets
Qtime:22
News from SeekingAlpha
04/13Key events next week - healthcare 
03/20Midday Gainers / Losers (03/20/2018) 
03/20HEALTHCARE - TOP 5 GAINERS / LOSERS : 15 am (3/20/2018) 
03/20PREMARKET GAINERS AS OF 9 : 05 am (03/20/2018) 
03/20Cardiome to divest Canadian business to Cipher Pharma for C$25.5M 
Chart CARDIOME PHARMA CORP
Duration : Period :
Cardiome Pharma Corp Technical Analysis Chart | COM | CA14159U3010 | 4-Traders
Technical analysis trends CARDIOME PHARMA CORP
Short TermMid-TermLong Term
TrendsBullishBullishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 3
Average target price 8,61  CAD
Spread / Average Target 195%
EPS Revisions
Managers
NameTitle
William L. Hunter President, Chief Executive Officer & Director
William James O'Shea Chairman
Sheila M. Grant Chief Operating Officer
Justin A. Renz Chief Financial Officer
Richard M. Glickman Lead Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
CARDIOME PHARMA CORP54.97%83
BIOGEN-17.44%56 705
CSL LIMITED13.09%56 258
ALEXION PHARMACEUTICALS-9.88%25 118
GRIFOLS-4.16%17 683
BIOMARIN PHARMACEUTICAL-7.70%14 864